상세정보
Export to Refworks부가기능
Implementation of lung cancer screening : proceedings of a workshop
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | Implementation of lung cancer screening : proceedings of a workshop/ Erin Balogh, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. |
| 개인저자 | Balogh, Erin,rapporteur. Patlak, Margie,rapporteur, Nass, Sharyl J.,rapporteur, |
| 단체저자명 | National Cancer Policy Forum (U.S.),sponsoring body. |
| 발행사항 | Washington, DC: the National Academies Press, [2017]. |
| 형태사항 | 1 online resource (1 PDF file (xxii, 105 pages)): illustrations. |
| 기타형태 저록 | Print version: Implementation of lung cancer screening. National Academies Press, 2017 9780309451321 |
| ISBN | 9780309451338 0309451337 |
| 서지주기 | Includes bibliographical references. |
| 내용주기 | Pages:1 to 25; Pages:26 to 50; Pages:51 to 75; Pages:76 to 100; Pages:101 to 125; Pages:126 to 129 |
| 요약 | The public health burden from lung cancer is substantial: it is the second most commonly diagnosed cancer and the leading cause of cancer-related deaths in the United States. Given the individual and population health burden of lung cancer, especially when it is diagnosed at later stages, there has been a push to develop and implement screening strategies for early detection. However, many factors need to be considered for broad implementation of lung cancer screening in clinical practice. Effective implementation will entail understanding the balance of potential benefits and harms of lung cancer screening, defining and reaching eligible populations, addressing health disparities, and many more considerations. In recognition of the substantial challenges to developing effective lung cancer screening programs in clinical practice, the National Academies of Sciences, Engineering, and Medicine held a workshop in June 2016. At the workshop, experts described the current evidence base for lung cancer screening, the current challenges of implementation, and opportunities to overcome them. Workshop participants also explored capacity and access issues; best practices for screening programs; assessment of patient outcomes, quality, and value in lung cancer screening; and research needs that could improve implementation efforts. This publication summarizes the presentations and discussions from the workshop. |
| 기금정보주기 | This project was supported by Contract No. 200-2011-38807 (Task Order No. 0051) and Contract No. HHSN263201200074I (Task Order No. HHSN26300052) with the Centers for Disease Control and Prevention and the National Cancer Institute/National Institutes of Health, respectively, and by the American Association for Cancer Research, American Cancer Society, American College of Radiology, American Society for Radiation Oncology, American Society of Clinical Oncology, American Society of Hematology, Association of American Cancer Institutes, AstraZeneca, Bristol-Myers Squibb, Cancer Support Community, CEO Roundtable on Cancer, Helsinn Healthcare SA, LIVESTRONG Foundation, National Comprehensive Cancer Network, Novartis Oncology, Oncology Nursing Society, and Pfizer Inc. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project. |
| 회의명 | Implementation of Lung Cancer Screening (Workshop) (2016 : Washington, D.C.) |
| 주제명(지명) | United States --epidemiology. |
| 일반주제명 | Lung Neoplasms --diagnosis. Lung Neoplasms --epidemiology. Mass Screening. Lungs --Cancer --Treatment --Congresses. Lungs --Cancer --Treatment. HEALTH & FITNESS / Diseases / General MEDICAL / Clinical Medicine MEDICAL / Diseases MEDICAL / Evidence-Based Medicine MEDICAL / Internal Medicine |
| 언어 | 영어 |
| 바로가기 |  |
